… As in many other connective tissue diseases, JLS mainly involves females with a F: M
ratio of 2–3: 1 [2••,22,23] . … 3 Zulian F, Martini G. Preliminary classification criteria for …

Purpose: The optimal treatment of systemic sclerosis (SSc) is a challenge because the
pathogenesis of SSc is unclear and it is an uncommon and clinically heterogeneous disease …

Background Conventional pharmacological therapies for the treatment of juvenile idiopathic
arthritis (JIA) consist of non-biological, disease-modifying antirheumatic drugs, among …

The aim was to update the 2009 European League against Rheumatism (EULAR)
recommendations for the treatment of systemic sclerosis (SSc), with attention to new therapeutic …

Background Systemic juvenile idiopathic arthritis (JIA) is the most severe subtype of JIA;
treatment options are limited. Interleukin-6 plays a pathogenic role in systemic JIA. Methods We …

Localized scleroderma (LS) is a complex disease characterized by a mixture of
inflammation and fibrosis of the skin that, especially in the pediatric population, also affects …

Objective. Juvenile localized scleroderma (JLS) includes a number of conditions often grouped
together. With the long-term goal of developing uniform classification criteria, we studied …

Objective To compare the safety and efficacy of parenteral methotrexate (MTX) at an intermediate
dosage (15 mg/m 2 /week) versus a higher dosage (30 mg/m 2 /week) in patients with …

Objective Juvenile localized scleroderma is usually considered a disease that is confined to
the skin and subcutaneous tissue. We studied the prevalence and clinical features of …

Objective To evaluate the safety and efficacy of infliximab in the treatment of juvenile rheumatoid
arthritis (JRA). Methods This was an international, multicenter, randomized, placebo‐…